9. Contrast-Induced Nephropathy — Reassessing an Established Diagnosis

Quick Recap

Cross-cutting protocol — companion to relevant Renal System AKI protocols. Addresses a genuinely unusual situation in modern medicine: a condition taught for decades as an established, causal entity, whose underlying causal premise has been substantially challenged by a wave of large, methodologically sophisticated propensity-matched and counterfactual studies — to the point that professional radiology and nephrology bodies have jointly stated the risk has been "overstated," while the two major prevention trials (sodium bicarbonate, N-acetylcysteine) have independently, definitively failed regardless of which side of the causal debate one takes.

1. Definition

Contrast-induced nephropathy (CIN) / contrast-induced acute kidney injury (CI-AKI): traditionally defined as an increase in serum creatinine (commonly ≥25% or ≥0.5 mg/dL from baseline) within 48–72 hours following intravascular iodinated contrast administration, attributed causally to the contrast agent itself — historically taught as the third leading cause of hospital-acquired AKI.

A deliberate, meaningful terminology shift, itself reflecting the underlying scientific controversy: the field has increasingly moved toward the terms "post-contrast AKI" (PC-AKI) or "contrast-associated AKI" (CA-AKI) — explicitly replacing "contrast-induced" with more causally neutral language. As one radiologist specifically explained regarding this shift: "'Contrast-induced' AKI implies a causal relationship. However, in many circumstances, the diagnosis of contrast-induced AKI in clinical care and in research is made in a way that prevents causal attribution" — "disentangling contrast-induced AKI (causal AKI) from contrast-associated AKI (correlated AKI) is a critical step forward." This protocol uses "contrast-induced nephropathy" in its title for recognizability, while treating the underlying causal question as the central, substantive content addressed throughout.

2. Pathophysiology

The traditionally taught mechanism involves medullary hypoxia (from contrast-induced renal vasoconstriction and altered regional blood flow) combined with direct tubular toxicity of the contrast agent — a biologically plausible mechanism that is not itself in dispute. The genuine controversy is not about whether this mechanism could theoretically cause kidney injury, but about how much of the observed, real-world association between contrast administration and subsequent AKI actually reflects this causal mechanism, versus confounding by the underlying illness severity, comorbidity burden, and clinical context that led to the patient receiving contrast in the first place — sicker patients, patients with unstable hemodynamics, and patients with more comorbidities are both more likely to receive contrast-enhanced imaging as part of their workup and more likely to develop AKI from their underlying condition regardless of contrast exposure, creating a structural confounding problem that simple before-after or contrast-vs-no-contrast comparisons cannot resolve.

3. Immediate Stabilization (ABCDE) — Not Applicable in the Traditional Sense

This protocol addresses a risk-assessment and prevention-strategy question rather than acute stabilization:

Checklist:

4. Focused History

• Baseline renal function (eGFR), specifically distinguishing the severe CKD population (eGFR <30) where a genuine signal for harm has been most consistently found
• Volume status and hemodynamic stability at the time of contrast administration
• Concurrent nephrotoxic exposures (other medications, hypotension) that may independently contribute to any observed post-procedure creatinine rise
• Clinical necessity and alternative imaging modality availability

5. Comprehensive System-wise Examination — Not a Primary Component

6. Syndrome Identification — Reframed as Evidence-Status Classification by Renal Function

• Normal or mildly reduced renal function (eGFR ≥60): the population where the most sophisticated, large-scale propensity-matched and counterfactual studies have consistently found no increased AKI risk attributable to contrast — clinically necessary contrast-enhanced imaging should not be withheld or delayed based on theoretical CIN risk in this population
• Moderately reduced renal function (eGFR 30–59): genuinely mixed evidence — some studies show a numerically higher but not statistically significant AKI rate with contrast; standard periprocedural precautions remain reasonable without strong evidence of a large, definitively causal effect
• Severe CKD (eGFR <30): the population where a genuine, more consistently replicated signal for contrast-attributable harm exists — Davenport et al.'s large propensity-matched study specifically found a significantly higher AKI rate with contrast exposure in this group (36.4% vs. 19.4%, OR 2.96, 95% CI 1.22–7.17) — this population warrants the most careful risk-benefit consideration and standard preventive measures
• Critically ill ICU patients, pre-CT eGFR ≤45: a specific, more nuanced finding — McDonald et al. found greater need for dialysis in this population (6.7% vs. 2.5%, OR 2.72) despite no corresponding impact on the standard AKI-by-creatinine-criterion outcome — a genuinely interesting dissociation suggesting the relationship between contrast exposure and clinically meaningful renal outcomes may be more complex in critically ill patients specifically than a simple creatinine-based AKI definition alone captures

7. Differential Diagnosis — The Central Content of This Protocol

The core diagnostic/attribution challenge this protocol addresses: when serum creatinine rises after a contrast-enhanced procedure, the differential includes true contrast-mediated nephrotoxicity alongside a substantial list of alternative, non-contrast-related explanations that are frequently the actual cause in the confounded, real-world clinical scenarios where CIN has traditionally been diagnosed:

Must-not-miss (alternative, non-contrast explanations for post-procedure creatinine rise):

• Underlying hemodynamic instability/hypotension during or around the procedure, independent of contrast itself
• Progression of the underlying critical illness or comorbidity that prompted the imaging in the first place
• Concurrent nephrotoxic medication exposure
• Cholesterol embolization syndrome (a genuine, distinct, contrast-procedure-associated but not contrast-mediated complication, particularly relevant after intra-arterial angiographic procedures)

The methodological key to distinguishing these: propensity-matched and counterfactual study designs (Section 11) were specifically developed to address exactly this attribution problem — comparing contrast-exposed and non-exposed patients matched on the confounders above, or comparing the same patient's creatinine trajectory after a contrast-enhanced vs. non-contrast-enhanced scan at different timepoints, to isolate contrast's specific, independent contribution from the broader clinical context.

8. Severity/Risk Assessment

eGFR as the dominant risk stratifier: current evidence most consistently supports a genuine, contrast-attributable risk specifically in severe CKD (eGFR <30), with progressively weaker and less consistent evidence for risk at higher eGFR levels — this represents a meaningfully more restrictive risk population than the traditionally taught "mild-to-moderate CKD, diabetes, or other comorbidity" risk framework.

A meta-analysis of over 100,000 patients in controlled studies found no significant association between contrast-enhanced CT and kidney injury — a large-scale synthesis reinforcing the individual propensity-matched study findings, though this conclusion remains actively debated (Section 23) by experts who point to methodologic limitations in some of the underlying studies.

9. Investigations

Serial creatinine monitoring: standard practice following contrast administration in at-risk patients, though current evidence should inform interpretation of any observed rise (i.e., not automatically attributing a post-procedure creatinine rise to the contrast itself without considering the broader clinical context per Section 7).

Kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL): a specific, mechanistically informative RCT (Kooiman et al.) found no increase in these specific tubular injury biomarkers following intravenous contrast-enhanced CT — a genuinely important finding suggesting that even when a creatinine-defined "CI-AKI" is diagnosed by traditional criteria, this may not be accompanied by actual, demonstrable kidney tubular damage — reinforcing the broader case that traditional creatinine-based diagnostic criteria may be capturing something other than genuine, contrast-mediated nephrotoxicity in many cases.

10. Point-of-Care Ultrasound — Not Applicable

11. Evidence-Based Management — Two Separate, Both Genuinely Important Evidence Threads

Thread One: Does Contrast Actually Cause AKI? — The Causal-Attribution Challenge

• Early, uncontrolled studies (Heller 1991, Polena 2005) found an increased AKI incidence among contrast recipients compared to non-recipients — but these studies failed to control for the confounding described in Section 2, comparing patients who received contrast (often because they were more stable, or because contrast was clinically necessary for a specific indication) against patients who did not (often for reasons related to their underlying instability or renal risk) — a structurally biased comparison
• McDonald et al., large propensity-score-matched studies (Radiology, 2013–2014, evaluating 21,346 patients): found no increased risk of AKI, emergent dialysis, or 30-day mortality between patients undergoing contrast-enhanced vs. non-contrast-enhanced CT, even among patients with compromised renal function or predisposing comorbidities
• A particularly elegant, genuinely persuasive study design — the counterfactual/within-patient analysis: McDonald et al. specifically examined creatinine changes in patients who underwent both a contrast-enhanced and a non-contrast CT scan at different points in time — essentially using each patient as their own control — and found no significant difference in AKI incidence between the two scan types in the same patient (McNemar test, χ²=0.63, p=0.43; OR 0.92, 95% CI 0.75–1.13) — this within-patient design specifically addresses the confounding-by-indication concern that limits between-patient comparisons, and represents one of the more methodologically compelling pieces of evidence in this literature
• Hinson et al.: a further, large, well-controlled study similarly found intravenous contrast was not associated with an increased frequency of AKI
• A genuine, still-standing exception — Davenport et al.: using a similar propensity-matching approach across over 17,000 patients, found AKI risk was significantly higher specifically in patients with eGFR <30 mL/min/1.73m² (36.4% vs. 19.4% with contrast, OR 2.96) — with progressively weaker, non-significant signals at higher eGFR strata, and no difference at all in patients with eGFR ≥60 — this remains the most consistently cited counterpoint to the broader "CIN is a myth" conclusion, and this protocol treats it as a genuine, real signal in this specific, severe-CKD population rather than dismissing it
• Biomarker-level reinforcement: the Kooiman RCT finding of no increase in KIM-1/NGAL (Section 9) provides mechanistic-level support for the propensity-matched studies' conclusion, suggesting the absence of AKI association in these studies is not simply an artifact of the specific matching methodology used

The Professional Response — "Overstated," But Not Universally Accepted as Fully Resolved

• American College of Radiology and National Kidney Foundation joint consensus statement (Davenport et al.): explicitly stated that contrast-induced nephropathy risk has been "overstated" in prior clinical teaching and practice, based on this accumulated propensity-matched and counterfactual evidence — a genuinely significant, practice-influencing position statement from two major relevant professional bodies
• This is not, however, a fully unanimous or closed scientific question: a meta-analysis of >100,000 patients found no significant association, but accompanying editorial commentary from other experts specifically pushed back, arguing that methodologic limitations in some of the underlying studies mean the existence of contrast-associated AKI as a real phenomenon is not simply "a myth" — and a dedicated re-analysis using the Bradford-Hill causality criteria concluded, more cautiously, "we are not sure" rather than declaring the causal question definitively resolved in either direction
• Practical synthesis of this first evidence thread: for the majority of patients, particularly those with preserved or moderately reduced renal function, current sophisticated evidence substantially undermines the traditional teaching that contrast administration carries a large, independently causal AKI risk — clinically necessary contrast-enhanced imaging should generally not be withheld or delayed based on this traditionally overstated concern. Severe CKD (eGFR <30) remains a population where a genuine, more consistently replicated risk signal persists, warranting continued careful risk-benefit consideration and standard precautions in this specific group.

Thread Two: Pharmacologic Prevention — Independently, Definitively Negative, Regardless of the Causal Debate Above

• PRESERVE trial (Weisbord et al., NEJM 2017): a large, multinational, 2×2 factorial RCT across 53 medical centers in the US, Australia, New Zealand, and Malaysia, n=5,177 (4,993 in the modified intention-to-treat analysis) with CKD stages III–IV scheduled for angiography — randomized to IV sodium bicarbonate vs. saline, and oral N-acetylcysteine vs. placebo
• Primary outcome: a major adverse kidney events (MAKE) composite — death, dialysis, or persistent ≥50% creatinine increase at 90 days — a deliberately more patient-centered, clinically meaningful endpoint than the traditional creatinine-rise-based CIN definition
• Result: the trial was stopped early after a prespecified interim analysis indicated a low likelihood of a meaningful difference — 4.7% (saline) vs. 4.4% (bicarbonate), p=0.62 — no benefit whatsoever for either sodium bicarbonate or N-acetylcysteine over standard saline/placebo
• Independent editorial commentary's direct assessment: "this trial would appear to put an end to the use of N-acetylcysteine or sodium bicarbonate solution in patients exposed to intra-arterial contrast" — a definitive, practice-clarifying conclusion following more than 40 prior prospective randomized trials (each individually mostly small and underpowered) that had left the field in genuine, unresolved equipoise for years
• TEATE trial (subsequent, corroborating evidence): found that while sodium bicarbonate administration did achieve more frequent urine alkalinization (the intended physiological target), the difference in CI-AKI rates was not significant compared to standard saline hydration — reinforcing PRESERVE's conclusion with an independent trial
• Practical significance of this second evidence thread: regardless of one's position on the broader causal-attribution debate in Thread One, the specific pharmacologic prevention strategies (sodium bicarbonate, N-acetylcysteine) that dominated decades of clinical practice and smaller-trial literature have been definitively shown not to work, in a large, rigorous, patient-centered-outcome trial — this is a genuinely settled conclusion within this protocol's overall more contested subject matter

Practical Synthesis

This protocol addresses two related but analytically distinct questions, with different degrees of resolution: (1) does contrast genuinely cause AKI in most patients — an actively contested, though substantially reweighted-toward-"less-risk-than-traditionally-taught" question, with severe CKD (eGFR <30) as the clearest remaining population of genuine concern; and (2) does pharmacologic prophylaxis (bicarbonate, NAC) prevent it — a definitively, independently resolved negative answer per PRESERVE, regardless of how question (1) is ultimately settled. Standard periprocedural hydration with isotonic fluid remains the most evidence-supported preventive measure available, particularly in the severe-CKD population where genuine risk signal persists, while sodium bicarbonate and N-acetylcysteine should not be relied upon as effective preventive pharmacotherapy. Clinically necessary contrast-enhanced imaging should generally not be withheld from patients with preserved-to-moderately-reduced renal function based on traditionally overstated CIN concerns — the diagnostic information gained frequently outweighs a renal risk that current, sophisticated evidence suggests is considerably smaller than historically taught for most patients.

12. Organ Support

Cross-reference relevant Renal System AKI protocols for the broader AKI diagnostic and management framework this specific, contrast-attribution question sits within.

13. Disease-Specific Therapy

• Standard periprocedural isotonic fluid hydration: the primary, most defensible preventive measure, particularly in patients with severe CKD
• Sodium bicarbonate: not supported as superior to standard saline per PRESERVE; may be considered for practical/logistic reasons (more convenient for emergent procedures, cost-efficient) rather than for a demonstrated efficacy advantage
• N-acetylcysteine: not supported as an effective preventive agent per PRESERVE and the broader trial literature
• Contrast volume minimization: a reasonable, low-risk practical measure independent of the broader causal debate, given contrast volume's role as a risk factor in the population (severe CKD) where genuine risk signal persists

14. Consultation Matrix

15. Monitoring Framework

• Laboratory: serial creatinine per standard practice, with interpretation informed by the broader clinical context per Section 7 rather than automatic attribution to contrast alone
• Escalation triggers: significant, progressive renal function decline → standard AKI workup per relevant Renal System protocols, actively considering the full differential (Section 7) rather than assuming contrast as the default explanation

16. ICU Bundle Checklist

17. Complications

Genuine, still-supported risk: AKI specifically in severe CKD (eGFR <30) following contrast exposure, per Davenport et al.'s propensity-matched finding

Traditionally overstated risk: AKI in patients with preserved-to-moderately-reduced renal function, per the large, methodologically sophisticated propensity-matched and counterfactual literature

Prevention: standard periprocedural hydration; contrast volume minimization where clinically feasible, particularly in severe CKD

18. Escalation & De-escalation — Not Applicable

19. ICU Discharge Criteria — Not Applicable

20. Documentation & Medicolegal Checklist

• Baseline renal function documented before contrast-enhanced imaging
• Rationale for imaging decision documented, particularly in severe CKD where risk-benefit consideration is most relevant
• Post-procedure creatinine trend documented with attention to the broader clinical context

21. Key Guidelines

• American College of Radiology/National Kidney Foundation consensus statement: contrast-induced AKI risk has been overstated in prior teaching; contrast-enhanced imaging should generally not be withheld from patients with preserved-to-moderately-reduced renal function based on this traditionally overstated concern
• Current practice, per PRESERVE, does not support routine sodium bicarbonate or N-acetylcysteine for prevention

22. Landmark Trials

23. Controversies

• This entire topic is itself a controversy about controversy — a genuinely unusual epistemic situation worth naming explicitly: the field has moved from near-universal acceptance of CIN as an established, causal, common entity to a state where major professional bodies (ACR/NKF) have explicitly stated the risk was "overstated," while other experts, in accompanying editorial commentary on the same underlying meta-analytic literature, explicitly push back that contrast-associated AKI is "not a myth" and point to genuine methodologic limitations in some of the reassuring studies — a dedicated Bradford-Hill-criteria-based re-analysis concluded with the deliberately unresolved title framing "we are not sure." This protocol treats this genuine, ongoing expert disagreement as the honest current state of the science, not a settled question in either direction.
• The severe-CKD (eGFR <30) exception deserves particular emphasis precisely because it complicates a simple "CIN is a myth" narrative: Davenport's finding of a real, substantial, statistically significant risk specifically in this population means the appropriate practical conclusion is not "contrast is always safe" but rather "the traditional risk teaching was overstated for most patients, while a genuine risk persists in a more narrowly defined, severe-CKD population" — a more nuanced position than either the traditional teaching or a wholesale dismissal of contrast nephrotoxicity would suggest.
• The dissociation between traditional creatinine-based AKI criteria and both dialysis need (McDonald's ICU-specific finding) and tubular injury biomarkers (Kooiman's RCT) raises a genuinely interesting methodological question about whether creatinine-based CI-AKI diagnosis is measuring the right thing at all — this is not fully resolved and represents an active area of nephrology/radiology methodological development (reflected in the deliberate shift toward "PC-AKI"/"CA-AKI" terminology) rather than a settled diagnostic framework.
• PRESERVE's definitive negative result for pharmacologic prevention stands somewhat independent of, and is more settled than, the broader causal-attribution debate: even experts who maintain that contrast-associated AKI represents a genuine, causal phenomenon in at least some patients broadly accept that sodium bicarbonate and NAC do not prevent it — this protocol treats these as two analytically separate conclusions with different degrees of certainty, rather than conflating "prevention doesn't work" with "therefore the condition doesn't exist," which would be a logical overreach not directly supported by PRESERVE's design or findings.

24. References

1. McDonald RJ, McDonald JS, Carter RE, Katzberg RW, Kallmes DF, Williamson EE. Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology. 2014;271(1):65-73.
2. McDonald JS, McDonald RJ, Comin J, et al. Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology. 2013;267(1):119-128.
3. McDonald RJ, McDonald JS, Bida JP, et al. Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology. 2013;267(1):106-118.
4. Davenport MS, Khalatbari S, Dillman JR, Cohan RH, Caoili EM, Ellis JH. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology. 2013;268(3):719-728.
5. Hinson JS, Ehmann MR, Fine DM, et al. Risk of acute kidney injury after intravenous contrast media administration. Ann Emerg Med. 2017;69(5):577-586.e4.
6. Kooiman J, van de Peppel WR, Sijpkens YWJ, et al. No increase in Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin excretion following intravenous contrast enhanced-CT. Eur Radiol. 2015;25:1926-1934.
7. Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020;294(3):660-668.
8. Weisbord SD, Gallagher M, Jneid H, et al; PRESERVE Trial Group. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med. 2018;378(7):603-614.
9. Newhouse JH, RoyChoudhury A. Quantitating contrast medium-induced nephropathy: controlling the controls. Radiology. 2013;267:4-8.
10. Contrast-associated acute kidney injury is a myth: we are not sure. Intensive Care Med. 2018;44(1):104-106.
11. Navigating nephrotoxic waters: a comprehensive overview of contrast-induced acute kidney injury prevention. 2024.
12. Contrast-Induced Acute Kidney Injury in the PRESERVE Trial: Lessons Learned. Clin J Am Soc Nephrol. 2018.
13. The Washington Manual of Critical Care, 4th ed. 2025 — acute kidney injury chapter.
14. ICU Protocols: A Step-wise Approach, 2nd ed. — relevant AKI content.